Back to News
Market Impact: 0.2
Pharvaris N.V. Consensus Price Target Raised 20.08% to $59.77
Source: Nasdaq
Analyst EstimatesHealthcare & Biotech
Fintel's aggregate one-year analyst price target for Pharvaris N.V. was raised 20.08% to $59.77 per share from $49.78 as of August 25, 2026. The upward revision signals improved analyst expectations for the biotech company, though the article provides no underlying earnings, clinical, or operational catalyst.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
PHVS0.45
More News
- Tech giants need legacy businesses to keep growing as they pour trillions into the AI buildout
- Illumina CEO on Q3 Results and Business Outlook
- UnitedHealth is finally getting its act together. I'm buying into the turnaround
- Swiss Firms Plan Investment Boost in China Drug, Finance Sectors
- Evercore ISI cuts Reddit stock rating on user growth concerns
- Bernstein SocGen raises Eli Lilly stock price target on strong Q3 beat